Given that LKB1, an upstream kinase of AMPK, is the leading mutated gene in lung adenocarcinoma, we sought to further confirm the above results using the LKB1-deficient KRAS-driven lung cancer model (KL). The gene discussed is PRKAA2; the disease is lung adenocarcinoma.